|Posted by australiandryeye on May 2, 2017 at 11:15 PM|
Allergan has gotten Food and Drug Administration approval to market its TrueTear Intranasal Tear Neurostimular, a device the company says increases tear production using electrical stimulation.
Allergan, with headquarters in Dublin and New Jersey, has a unit in Irvine, where it was previously based until it was acquired for about $70 billion by Dublin-based Actavis Plc.
TrueTear, Allergan said in a statement, is the first FDA-approved device to increase tear production in adult patients using neurostimulation. The handheld stimulator includes disposable tips that are placed in the nasal cavity, which induces tear production.
“TrueTear represents a technological breakthrough for eye care professionals as it delivers an effective, non-invasive and drug-free way to temporarily increase tear production,” David Nicholson, chief research and development officer, at Allergan, said in a statement. “As an innovator in eye care, we are continually looking for new products to offer through our portfolio, and TrueTear represents the next step forward.”
Allergan has long been rooted in the eye care industry. In the early 1950s, it developed eye drops to treat allergies and acts as decongestants.